Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

Conditions

• Amblyopia

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• N/A this is an observational study of Standard of Care — DEVICE
  Medical Device which treats unilateral amblyopia through therapeutic software which stimulate vision

Study Details

Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may also have measurable dysfunction of accommodation, fixation, binocularity, vergence, reading fluency, depth perception, and contrast sensitivity. For the first time since the incorporation of atropine penalization into amblyopia management, physicians can now offer Luminopia, an FDA-approved dual action dichoptic treatment, to patients with amblyopia. Since the product became commercially available in November 2022, the number of patients on Luminopia therapy continues to grow. This presents a unique opportunity to gather real world evidence from a large number of patients, representative of how ophthalmologists and optometrists are applying this novel treatment in the real world. A registry of the clinical data associated with Luminopia treatment, with IRB oversight, will provide answers to key scientific questions using a large dataset.

Key Dates

Start date

Sep 1, 2023

Status verified

Sep 2025

Primary completion

Dec 31, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

500 participants (estimated)

Primary Outcome Measure

Change in Visual Acuity from baseline to consecutive visits [ Time Frame: 3, 6,12, 24 months ]

Locations (13)

Find similar trials in San Ramon, CA

Related Studies

• Binocular Amblyopia Treatment
  Recruiting · Retina Foundation of the Southwest · Dallas, Texas
• A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
  PHASE3 · Recruiting · Jaeb Center for Health Research · Birmingham, Alabama
• Video Treatment for Amblyopia
  Recruiting · Retina Foundation of the Southwest · Dallas, Texas
• Patch-free Occlusion Therapy
  Recruiting · Retina Foundation of the Southwest · Dallas, Texas